1. 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy
- Author
-
Li, J, Lindstroem, LS, Foo, JN, Rafiq, S, Schmidt, MK, Pharoah, PDP, Michailidou, K, Dennis, J, Bolla, MK, Wang, Q, Van't Veer, LJ, Cornelissen, S, Rutgers, E, Southey, MC, Apicella, C, Dite, GS, Hopper, JL, Fasching, PA, Haeberle, L, Ekici, AB, Beckmann, MW, Blomqvist, C, Muranen, TA, Aittomaeki, K, Lindblom, A, Margolin, S, Mannermaa, A, Kosma, V-M, Hartikainen, JM, Kataja, V, Chenevix-Trench, G, Phillips, K-A, McLachlan, S-A, Lambrechts, D, Thienpont, B, Smeets, A, Wildiers, H, Chang-Claude, J, Flesch-Janys, D, Seibold, P, Rudolph, A, Giles, GG, Baglietto, L, Severi, G, Haiman, CA, Henderson, BE, Schumacher, F, Le Marchand, L, Kristensen, V, Alnaes, GIG, Borresen-Dale, A-L, Nord, S, Winqvist, R, Pylkas, K, Jukkola-Vuorinen, A, Grip, M, Andrulis, IL, Knight, JA, Glendon, G, Tchatchou, S, Devilee, P, Tollenaar, R, Seynaeve, C, Hooning, M, Kriege, M, Hollestelle, A, Van den Ouweland, A, Li, Y, Hamann, U, Torres, D, Ulmer, HU, Rudiger, T, Shen, C-Y, Hsiung, C-N, Wu, P-E, Chen, S-T, Teo, SH, Taib, NAM, Yip, CH, Ho, GF, Matsuo, K, Ito, H, Iwata, H, Tajima, K, Kang, D, Choi, J-Y, Park, SK, Yoo, K-Y, Maishman, T, Tapper, WJ, Dunning, A, Shah, M, Luben, R, Brown, J, Khor, CC, Eccles, DM, Nevanlinna, H, Easton, D, Humphreys, K, Liu, J, Hall, P, Czene, K, Li, J, Lindstroem, LS, Foo, JN, Rafiq, S, Schmidt, MK, Pharoah, PDP, Michailidou, K, Dennis, J, Bolla, MK, Wang, Q, Van't Veer, LJ, Cornelissen, S, Rutgers, E, Southey, MC, Apicella, C, Dite, GS, Hopper, JL, Fasching, PA, Haeberle, L, Ekici, AB, Beckmann, MW, Blomqvist, C, Muranen, TA, Aittomaeki, K, Lindblom, A, Margolin, S, Mannermaa, A, Kosma, V-M, Hartikainen, JM, Kataja, V, Chenevix-Trench, G, Phillips, K-A, McLachlan, S-A, Lambrechts, D, Thienpont, B, Smeets, A, Wildiers, H, Chang-Claude, J, Flesch-Janys, D, Seibold, P, Rudolph, A, Giles, GG, Baglietto, L, Severi, G, Haiman, CA, Henderson, BE, Schumacher, F, Le Marchand, L, Kristensen, V, Alnaes, GIG, Borresen-Dale, A-L, Nord, S, Winqvist, R, Pylkas, K, Jukkola-Vuorinen, A, Grip, M, Andrulis, IL, Knight, JA, Glendon, G, Tchatchou, S, Devilee, P, Tollenaar, R, Seynaeve, C, Hooning, M, Kriege, M, Hollestelle, A, Van den Ouweland, A, Li, Y, Hamann, U, Torres, D, Ulmer, HU, Rudiger, T, Shen, C-Y, Hsiung, C-N, Wu, P-E, Chen, S-T, Teo, SH, Taib, NAM, Yip, CH, Ho, GF, Matsuo, K, Ito, H, Iwata, H, Tajima, K, Kang, D, Choi, J-Y, Park, SK, Yoo, K-Y, Maishman, T, Tapper, WJ, Dunning, A, Shah, M, Luben, R, Brown, J, Khor, CC, Eccles, DM, Nevanlinna, H, Easton, D, Humphreys, K, Liu, J, Hall, P, and Czene, K
- Abstract
Large population-based registry studies have shown that breast cancer prognosis is inherited. Here we analyse single-nucleotide polymorphisms (SNPs) of genes implicated in human immunology and inflammation as candidates for prognostic markers of breast cancer survival involving 1,804 oestrogen receptor (ER)-negative patients treated with chemotherapy (279 events) from 14 European studies in a prior large-scale genotyping experiment, which is part of the Collaborative Oncological Gene-environment Study (COGS) initiative. We carry out replication using Asian COGS samples (n=522, 53 events) and the Prospective Study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) study (n=315, 108 events). Rs4458204_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n=2,641, 440 events, combined allelic hazard ratio (HR)=1.81 (1.49-2.19); P for trend=1.90 × 10(-9)). Such survival-associated variants can represent ideal targets for tailored therapeutics, and may also enhance our current prognostic prediction capabilities.
- Published
- 2014